Association between psoriasis and cardiovascular risk factors in korean patients

Annals of Dermatology

Volumn 22, Issue 3, 2010, Pages 300-306

  Choi, Woo Jin ^a   Park, Eun Joo ^a   Kwon, In Ho ^a   Kim, Kwang Ho ^a   Kim, Kwang Joong ^a  

^a Hallym University   (South Korea)

Author keywords

Cardiovascular risk factor; Framingham risk score; Metabolic syndrome; Psoriasis

Indexed keywords

EID: 77957912352     PISSN: 10139087     EISSN: None     Source Type: Journal    
DOI: 10.5021/ad.2010.22.3.300     Document Type: Article

References (36)

1. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407.
2. Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352: 1899-1912.
3. Federman DG, Shelling M, Prodanovich S, Gunderson CG, Kirsner RS. Psoriasis: an opportunity to identify cardiovascular risk. Br J Dermatol 2009; 160: 1-7.
4. Griffiths CE, laccarino L, Naldi L, Olivieri I, Pipitone N, Salvarani C, et al. Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. Clin Exp Rheumatol 2006; 24(1 Suppl 40): S72-78.
5. Terui T, Ozawa M, Tagami H. Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammationboosting loop. Exp Dermatol 2000; 9: 1-10. (Pubitemid 30093030)
6. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-986.
7. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-155.
8. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 1999; 41: S7-S12. (Pubitemid 29416461)
9. Taler SJ, Textor SC, Canzanello VJ, Schwartz L. Cyclosporininduced hypertension: incidence, pathogenesis and management. Drug Saf 1999; 20: 437-449.
10. Dierkes J, Westphal S. Effect of drugs on homocysteine concentrations. Semin Vase Med 2005; 5: 124-139.
11. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-1062. (Pubitemid 41338752)
12. Bae SJ, Lee MK. Definition and diagnosis of the metabolic syndrome. J Korean Med Assoc 2005; 48: 1157-1164.
13. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286: 180-187. (Pubitemid 32640849)
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
15. O'Malley T, Ludlam CA, Riemermsa RA, Fox KA. Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk factor for the acute coronary syndromes. Eur Heart J 2001; 22: 1226-1234. (Pubitemid 32702959)
16. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
17. Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulln plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol 2004; 18: 180-183. (Pubitemid 38379896)
18. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565. (Pubitemid 35315836)
19. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/ HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. ArteriosclerThromb Vase Biol 2009; 29: 424-430.
20. Wolf N, Quaranta M, Prescott NJ, Allen M, Smith R, Burden AD, et al. Psoriasis is associated with pleiotrope susceptibility loci identified in type Il diabetes and Crohn disease. J Med Genet 2008; 45: 114-116. (Pubitemid 351252875)
21. Campalani E, Allen MH, Fairhurst D, Young HS, Mendonça CO, Burden AD, et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 2006; 154: 345-352. (Pubitemid 43382709)
22. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009; 41: 199-204.
23. Boonyasrisawat W, Eberle D, Bacci S, Zhang YY, Nolan D, Cervino EV, et al. Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. Diabetes 2007; 56: 499-505. (Pubitemid 46263095)
24. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-1534. (Pubitemid 41815842)
25. Mailbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-230. (Pubitemid 38461682)
26. Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007; 56: 629-634. (Pubitemid 46400186)
27. Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol 2010; 90: 23-26.
28. Cohen AD, Gilutz H, Henkin Y, Zahger D, Shapiro J, Bonneh DY, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007; 87: 506-509.
29. Akhyani M, Ehsani AH, Robati RM, Robati AM. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol 2007; 21: 1330-1332. (Pubitemid 350020138)
30. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73. (Pubitemid 46934281)
31. Xiao J, Chen LH, Tu YT, Deng XH, Tao J. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol 2009; 23: 1311-1315.
32. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009; 145: 700-703.
33. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51: 563-569.
34. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002; 136: 157-160.
35. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991; 303: 276-282.
36. Stern RS. Psoriasis Is not a useful independent risk factor for cardiovascular disease. J Invest Dermatol 2010; 130: 917-919.